New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD) roche.com
Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension roche.com
European Commission approves Roche’s Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy roche.com
Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies roche.com
